NoorSadaNoorSada
BREAKINGEconomyDeveloping✓ 2 sources

This story is currently available in anglais only — a translation isn't ready yet.

Bektenov Discusses Healthcare Investment with Foreign Pharmaceutical Companies in Kazakhstan

Investment Climate Improvement Council: the pharmaceutical market grew 31% to 1.2 trillion tenge, with eight projects worth 390 billion tenge under review.

Vitesse:

ℹ️ Lecture par le navigateur · voix studio IA bientôt

AK
Anna Kuznetsova
· 2 min read
USD/KZT, last 30 days · NoorSada · Yahoo Finance

Prime Minister of Kazakhstan Olzhas Bektenov held a meeting of the Investment Climate Improvement Council, where he discussed investment cooperation in healthcare with representatives of international business: pharmaceutical production, access to modern methods of treatment and improvement of the investment environment.

Bektenov noted that protection of public health has been enshrined in Kazakhstan's Constitution for the first time, and pointed to plans to accelerate the construction of medical facilities with private sector participation. According to him, the government is implementing the Healthcare Development Concept through 2029 and the Healthcare Infrastructure Development Concept for 2024-2030; the documents provide for "improving medical care, introducing innovative technologies and strengthening pharmaceutical security."

The measures are already producing results, the prime minister said: life expectancy in Kazakhstan has approached 76 years, the rural healthcare modernization project has expanded access to medical services for around 1 million people, more than 800 medical facilities have been built in the regions over the past three years, with another 70 planned. Projects to build multidisciplinary, university and children's hospitals are being implemented with the participation of foreign investors and international financial institutions.

Separate attention was given to pharmaceuticals. The market last year exceeded 1.2 trillion tenge (about $2.7 billion), showing growth of 31%. Eight major investment projects worth more than 390 billion tenge (about $878 million) are under review: they are designed to produce around 500 types of medicines and create new jobs. In April, Kazakhstan became the first CIS country to reach the third level of maturity of its national regulatory system under the World Health Organization methodology. A "single window" mechanism and an accelerated drug registration procedure of 15 working days for medicines from countries with high regulatory standards have been introduced.

Speaking at the meeting were Executive Director of the American Chamber of Commerce in Kazakhstan (AmCham) Jeff Erlich, U.S. Ambassador to Kazakhstan Julie Stufft, General Director of Johnson & Johnson Kazakhstan Adilet Nazarbayev, General Director of AstraZeneca Kazakhstan Elena Trogova and Pfizer Regional Director for Kazakhstan, Central Asia, the Caucasus and Mongolia Dmitry Kozenkov.

Stufft emphasized the importance of a stable and predictable investment environment in healthcare and pharmaceuticals and of improving access to medicines. Nazarbayev raised issues of improving the mechanisms for including drugs in the state reimbursement list and of gradually increasing healthcare financing. Trogova spoke about access to vital medicines for patients with rare diseases, Kozenkov about further localization of production, protection of intellectual property and predictable regulation.

Following the meeting, Bektenov instructed the relevant state bodies to work through the proposals of foreign pharmaceutical companies and to develop measures to improve the investment climate in the sector — attracting investment, localizing pharmaceutical production, introducing advanced technologies and expanding access to quality medical care.

Sources — how we know this

2 independent sources corroborated this

#Economy○ ...#Health○ ...